Coherus Biosciences, Inc. (CHRS): Jean-frederic Viret , Chief Financial Officer of Coherus Biosciences, Inc. sold 3,900 shares on Sep 26, 2016. The Insider selling transaction was reported by the company on Sep 28, 2016 to the Securities and Exchange Commission. The shares were sold at $29.89 per share for a total value of $116,549.94 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 22, 2016, Dennis M Lanfear (President and CEO) sold 4,060 shares at $31.75 per share price.On Sep 6, 2016, Alan C. Herman (Chief Scientific Officer) sold 16,999 shares at $29.99 per share price.Also, On Aug 10, 2016, Peter K. Watler (Chief Technical Officer) sold 55,621 shares at $30.00 per share price.On Aug 10, 2016, Llc Fmr (other) sold 100,000 shares at $29.88 per share price.
Coherus Biosciences Inc: On Tuesday, Sep 27, 2016 heightened volatility was witnessed in Coherus Biosciences Inc which led to swings in the share price. The shares opened for trading at $30.23 and hit $31.12 on the upside , eventually ending the session at $30.92, with a gain of 4.14% or 1.23 points. The heightened volatility saw the trading volume jump to 4,97,935 shares. The 52-week high of the share price is $31.98 and the company has a market cap of $1,341 M . The 52-week low of the share price is at $12.04.
Company has been under the radar of several Street Analysts.Coherus Biosciences Inc is Initiated by Maxim Group to Buy and the brokerage firm has set the Price Target at $43. The Rating was issued on Sep 7, 2016.Coherus Biosciences Inc is Initiated by Citigroup to Buy and the brokerage firm has set the Price Target at $36. The Rating was issued on Jul 27, 2016.
Coherus BioSciences Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Company’s clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (TNF) and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Company’s product pipeline includes anti-TNF product candidate CHS-0214 an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials and anti-TNF product candidate CHS-1420 an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate CHS-1701 a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.